Zura Bio (ZURA) Competitors $1.50 +0.10 (+7.14%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.50 0.00 (0.00%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZURA vs. SVRA, KMDA, CMPX, PVLA, FULC, GOSS, TECX, ETON, AQST, and ARCTShould you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Savara (SVRA), Kamada (KMDA), Compass Therapeutics (CMPX), Palvella Therapeutics (PVLA), Fulcrum Therapeutics (FULC), Gossamer Bio (GOSS), Tectonic Therapeutic (TECX), Eton Pharmaceuticals (ETON), Aquestive Therapeutics (AQST), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Zura Bio vs. Its Competitors Savara Kamada Compass Therapeutics Palvella Therapeutics Fulcrum Therapeutics Gossamer Bio Tectonic Therapeutic Eton Pharmaceuticals Aquestive Therapeutics Arcturus Therapeutics Savara (NASDAQ:SVRA) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends. Is SVRA or ZURA more profitable? Zura Bio's return on equity of -42.84% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets SavaraN/A -65.88% -52.35% Zura Bio N/A -42.84%-35.22% Do insiders & institutionals have more ownership in SVRA or ZURA? 87.9% of Savara shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 14.2% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, SVRA or ZURA? Savara has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Do analysts prefer SVRA or ZURA? Savara presently has a consensus target price of $5.60, suggesting a potential upside of 116.22%. Zura Bio has a consensus target price of $14.33, suggesting a potential upside of 855.56%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts clearly believe Zura Bio is more favorable than Savara.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Savara 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Zura Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has higher valuation & earnings, SVRA or ZURA? Savara is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSavaraN/AN/A-$95.88M-$0.48-5.40Zura BioN/AN/A-$45.39M-$0.70-2.14 Does the media favor SVRA or ZURA? In the previous week, Savara had 1 more articles in the media than Zura Bio. MarketBeat recorded 1 mentions for Savara and 0 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.11 beat Savara's score of 0.00 indicating that Zura Bio is being referred to more favorably in the news media. Company Overall Sentiment Savara Neutral Zura Bio Positive SummaryZura Bio beats Savara on 10 of the 14 factors compared between the two stocks. Get Zura Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZURA vs. The Competition Export to ExcelMetricZura BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.56M$3.01B$5.52B$9.37BDividend YieldN/A2.44%4.74%4.13%P/E Ratio-2.1417.8528.9923.78Price / SalesN/A309.13440.5196.33Price / CashN/A41.6335.0756.59Price / Book0.668.488.255.54Net Income-$45.39M-$55.06M$3.25B$259.97M7 Day Performance-8.54%-3.99%-3.75%-4.67%1 Month Performance32.04%8.53%2.99%3.29%1 Year Performance-58.79%6.51%25.34%17.92% Zura Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZURAZura Bio3.6284 of 5 stars$1.50+7.1%$14.33+855.6%-58.8%$102.56MN/A-2.143News CoveragePositive NewsSVRASavara1.4731 of 5 stars$2.66+3.1%$5.60+110.5%-37.7%$445.92MN/A-5.5420High Trading VolumeKMDAKamada4.4774 of 5 stars$7.68-0.5%$13.00+69.3%+34.2%$443.94M$160.95M26.48360News CoveragePositive NewsCMPXCompass Therapeutics2.3758 of 5 stars$3.20+0.6%$12.67+295.8%+196.3%$439.74M$850K-7.8020News CoverageGap DownPVLAPalvella Therapeutics2.6776 of 5 stars$39.87+3.2%$47.50+19.1%N/A$426.97M$42.81M-3.30N/AGap UpFULCFulcrum Therapeutics2.2574 of 5 stars$7.81flat$6.29-19.5%-28.5%$421.58M$80M-111.56100Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionGOSSGossamer Bio3.9138 of 5 stars$1.98+7.6%$8.25+316.7%+124.2%$418.24M$124.59M-8.61180News CoveragePositive NewsOptions VolumeTECXTectonic Therapeutic2.8939 of 5 stars$22.74+1.9%$80.33+253.3%+20.9%$416.77MN/A-3.11120News CoverageETONEton Pharmaceuticals1.8804 of 5 stars$15.03-2.4%$29.67+97.4%+294.7%$412.99M$39.01M-83.5020News CoverageUpcoming EarningsAQSTAquestive Therapeutics1.8531 of 5 stars$4.00-3.6%$10.14+153.6%+11.0%$412.21M$57.56M-6.78160Upcoming EarningsARCTArcturus Therapeutics3.0195 of 5 stars$14.38-3.7%$54.00+275.5%-40.1%$405.18M$152.31M-5.68180Positive News Related Companies and Tools Related Companies SVRA Alternatives KMDA Alternatives CMPX Alternatives PVLA Alternatives FULC Alternatives GOSS Alternatives TECX Alternatives ETON Alternatives AQST Alternatives ARCT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZURA) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zura Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
